Fas-mediated apoptosis in Jurkat cells is suppressed in the pre-G2/M phase
Tóm tắt
The relationship between the cell cycle and Fas-mediated apoptosis was investigated using Jurkat cells. Analysis of the inducibility of apoptosis by anti-Fas antibody during the cell cycle synchronized by the thymidine double-block method, showed that apoptosis was induced in only 50% of the G2/M phase cells, while most of cells in the other phases underwent apoptosis. These observations indicate that G2/M phase cells are more resistant to Fas-mediated apoptosis than cells in other phases. Furthermore, a detailed analysis of G2/M phase found that only 20–30% of the cells underwent apoptosis 12 h after the removal of the second thymidine block (pre-G2/M phase). This suggests that Fas-mediated apoptosis is potently suppressed during the pre-G2/M phase. A possible explanation for the observation that cells in the pre-G2/M phase are less sensitive to anti-Fas antibody is lower expression level of Fas. To test this possibility, Fas expression levels on the cell surface during the cell cycle were examined. The content of Fas on the cell surface, however, did not change appreciably during the cell cycle. Thus, the suppression of apoptosis in the pre-G2/M phase is determined downstream after the receipt of the apoptotic signal through Fas.
Tài liệu tham khảo
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 1995; 58: 175-180.
Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
Miyawaki T, Uehara T, Tsuji T, et al. Differential expression of apoptosis-related CD95 antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753-3760.
Klas C, Debatin KM, Jonker R, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5: 625-630.
Beletskaya IV, Nikonova LV, Beletsky IP. Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Lett 1997; 412: 91-93.
Dao T, Huleatt JW, Hingorani R, Crispe N. Specific resistance of T cells to CD95-induced apoptosis during S phase of the cell cycle. J Immunol 1997; 159: 4261-4267.
Li-Weber M, Salgame P, Krammer PH, et al. Differential interaction of nuclear factors with the PRE-1 enhancer element of human IL-4 promoter in different T cell subsets. Blood 1997; 97: 1194-1200.
Juo P, Kuo CJ, Reynols SE, et al. Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997; 17: 24-35.
Lenczowski JM, Dominguez L, Eder AM, et al. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol Cell Biol 1997; 17: 170-181.
Ponton A, Clément M-V, Stamenkovic I. The CD95 (APO-1/Fas) receptor activates NF-kB independently of its cytotoxic function. J Biol Chem 1996; 271: 8991-8995.
Eischen CM, Dick CJ, Leibson J. Tyrosine kinase activation provides an early and requisite signal for Fas-induced apoptosis. J Immunol 1994; 153: 1947-1954.
Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Unscheduled activation of Cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995; 55: 228-231.
Shiokawa D, Ohyama H, Yamada T, Takahashi K, Tanuma S. Identification of an endonuclease responsible for apoptosis in rat thymocytes. Eur J Biochem 1994; 226: 23-30.
Tanuma S, Shiokawa D. Multiple forms of nuclear deoxyribonuclease in rat thymocytes. Biochem Biophys Res Comm 1994; 203: 789-797.
Huschtscha LI, Jeitner TM, Andersson CE, Bartier WA, Tattersall MHN. Identification of apoptotic and necrotic human leukemic cells by flow cytometry. Exp Cell Res 1994; 212: 161-165.
Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther 1996; 38: 495-504.
Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble from of the Fas molecule. Science 1994; 263: 1759-1762.
Schattner EJ, Elkon KB, Yoo D, et al. CD40 ligation induces apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557-1565.
Rathmell JC, Townsend SE, Xu JC, et al. Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-329.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
Takahashi, T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993; 178: 2231-2235.
Dianzani U, Bragardo M, Ramenghi U, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997; 89: 2871-2879.
Puck JM, Sneller MC. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Semin Immunol 1997; 9: 77-84.
Li F, Ambrosini G, Altieri DC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
Furukawa Y, Iwase A, Terui J, et al. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J Biol Chem 1996; 271: 28469-28477.
Kitagawa M, Okabe T, Yasuda H, et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 1993; 8: 2425-2432.
Salvesen GS, Dixit VM. Caspases: intercellular signaling by proteolysis. Cell 1997; 91: 443-446.
Shiokawa D, Nishimura K, Maruta H, Tanuma S. DNA fragmentation during thymic apoptosis is catalyzed by DNase γ. Apoptosis 1996; 1: 147-152.
Enari M, Sakahira H, Nagata S, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.